Portal de Periódicos da CAPES

Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up

1998; Wiley; Volume: 79; Issue: 1 Linguagem: Inglês

10.1002/(sici)1097-0215(19980220)79

1097-0215

Silvio Veronese, Francesco Mauri, Orazio Caffo, Monica Scaioli, D Aldovini, Giorgio Perrone, Enzo Galligioni, Claudio Doglioni, Paolo Palma, Mattia Barbareschi,

Cell death mechanisms and regulation

International Journal of CancerVolume 79, Issue 1 p. 13-18 Predictive Oncology - Human CancerFree Access Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up Silvio Veronese, Silvio Veronese Department of Histopathology, Niguarda-Ca'Granda Hospital, Milano, ItalySearch for more papers by this authorFrancesco A. Mauri, Francesco A. Mauri Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorOrazio Caffo, Orazio Caffo Department of Medical Oncology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorMonica Scaioli, Monica Scaioli Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorDaniela Aldovini, Daniela Aldovini Department of Histopathology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorGiorgio Perrone, Giorgio Perrone Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorEnzo Galligioni, Enzo Galligioni Department of Medical Oncology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorClaudio Doglioni, Claudio Doglioni Department of Histopathology, City Hospital of Belluno, Belluno, ItalySearch for more papers by this authorPaolo Dalla Palma, Paolo Dalla Palma Department of Histopathology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorMattia Barbareschi, Corresponding Author Mattia Barbareschi barbareschi@iol.it Department of Histopathology, St. Chiara Hospital, Trento, ItalyReparto di Anatomia Patologica, Ospedale St. Chiara, 38100 Trento, Italy. Fax: 39-461-903389Search for more papers by this author Silvio Veronese, Silvio Veronese Department of Histopathology, Niguarda-Ca'Granda Hospital, Milano, ItalySearch for more papers by this authorFrancesco A. Mauri, Francesco A. Mauri Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorOrazio Caffo, Orazio Caffo Department of Medical Oncology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorMonica Scaioli, Monica Scaioli Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorDaniela Aldovini, Daniela Aldovini Department of Histopathology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorGiorgio Perrone, Giorgio Perrone Department of Histopathology, S.S. Trinità Hospital, Borgomanero, ItalySearch for more papers by this authorEnzo Galligioni, Enzo Galligioni Department of Medical Oncology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorClaudio Doglioni, Claudio Doglioni Department of Histopathology, City Hospital of Belluno, Belluno, ItalySearch for more papers by this authorPaolo Dalla Palma, Paolo Dalla Palma Department of Histopathology, St. Chiara Hospital, Trento, ItalySearch for more papers by this authorMattia Barbareschi, Corresponding Author Mattia Barbareschi barbareschi@iol.it Department of Histopathology, St. Chiara Hospital, Trento, ItalyReparto di Anatomia Patologica, Ospedale St. Chiara, 38100 Trento, Italy. Fax: 39-461-903389Search for more papers by this author First published: 06 December 1998 https://doi.org/10.1002/(SICI)1097-0215(19980220)79:1 3.0.CO;2-ZCitations: 30AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Bax and Bc12 are functionally antagonistic proteins which control apoptosis, whose expression in human tumours could be of prognostic value. We evaluated Bax and Bcl2 expression in 239 breast carcinomas (99 N0, 140 N1/2) with long term follow-up (median 79 months, range 11–140) in relation to clinico-pathologic parameters, clinical outcome, adjuvant therapy and expression of oestrogen receptor protein and p53. The prognostic value of Bax was investigated in the whole series of patients and in subgroups of homogeneously staged and treated patients (i.e., node-negative, N1/2 CMF-treated, N1/2 tamoxifen-treated). Bax immunostaining was cytoplasmic and heterogeneous. Cases were scored as Bax-positive if there were more than 20% reacting cells. High Bax expression was associated with positive nodal status (p = 0.03) and high Bcl2 expression (p = 0.01) and was more frequent in high-grade tumours. In the node-negative subgroup, Bax expression was associated with small tumour size. No association was seen with other parameters or with clinical outcome in any subgroup of patients. Since the apoptotic rate of a tumour is influenced by the ratio Bcl2/Bax, we investigated the combined effects of Bax and Bcl2 expression in relation to clinical outcome. However, no differences in survival were seen in the Bcl2-negative and Bcl2-positive groups when they were subdivided on the basis of the level of Bax expression and vice versa. In experimental systems, p53 is a direct transcriptional activator of the human bax gene. However, we could not observe any relation between Bax and p53 expression. We investigated whether the combined p53/Bax expression could have any prognostic value since it is predicted that tumours with normal p53 expression and concurrent high levels of Bax should be less aggressive and more susceptible to therapy. However, while p53 itself was of prognostic value, Bax expression was not related to prognosis in p53-negative or in p53-positive groups. Int. J. Cancer (Pred. Oncol.) 79:13–18, 1998.© 1998 Wiley-Liss, Inc. Citing Literature Volume79, Issue120 February 1998Pages 13-18 ReferencesRelatedInformation